FIELD: medicine.
SUBSTANCE: invention refers to compounds of general formula (1)
shown below, or their pharmaceutically acceptable salts having pharmacological activity towards sigma receptor, to methods for producing these compounds and to pharmaceutical compositions containing them, and to using them for treating and/or preventing sigma receptor-related diseases. In the compounds of formula (I), R1 represents phenyl substituted by halogen atoms; naphthyl; C5-6 cycloalkyl; or quinolyl; R2 and R3 are independently specified in H and C1-6 alkyl group; R4 and R5 together with the nitrogen atom to which they are attached, form a substituted or unsubstituted 5-6-merous heterocyclyl group with one or two heteroatoms specified in O or N, wherein the substitute is specified in C1-6alkyl and C1-6alkanoyl; X represents an oxygen atom or a CH2 group; m is specified in 1, 2, 3 and 4; and n is specified in 1, 2, 3 and 4.
EFFECT: higher efficacy.
13 cl, 2 tbl, 50 ex
Title | Year | Author | Number |
---|---|---|---|
SIGMA-RECEPTOR INHIBITORS | 2005 |
|
RU2417987C2 |
SALTS OF 1-(4-(2-((1-(3,4-DIFLUOROPHENYL)-1N-PYRAZOL-3-YL)METHOXY)ETHYL)PIPERAZIN-1-YL)ETHANONE | 2016 |
|
RU2727974C2 |
SIGMA-RECEPTOR INHIBITORS | 2005 |
|
RU2404972C2 |
POLYCYCLIC SUBSTITUTED PYRAZOLE KINASE ACTIVITY INHIBITORS AND USE THEREOF | 2014 |
|
RU2655921C2 |
PHOSPHOINOSITIDE-3-KINASE INHIBITORS AND METHODS FOR USE THEREOF | 2007 |
|
RU2468027C2 |
USE OF SIGMA LIGANDS FROM PAIN IN BONE CANCER | 2011 |
|
RU2585095C2 |
PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2013 |
|
RU2623221C2 |
SUBSTITUTED PYRAZOLES | 2001 |
|
RU2286343C2 |
INDOLE COMPOUNDS AS CELL NECROSIS INHIBITORS | 2008 |
|
RU2477282C2 |
1,5-NAPHTHRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THEM | 2012 |
|
RU2645339C1 |
Authors
Dates
2016-04-27—Published
2011-05-26—Filed